Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357040 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Effects of Nitrous Oxide
A Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 2
- Study locations
NCT05357040: Recruiting Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by University of Chicago.
NCT05357040 is a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 172 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357040, a Phase 2 study of Major Depressive Disorder and Treatment-Resistant Depression, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nitrous oxide gas for inhalation
Study Locations (2)
Illinois
- University of Chicago Medicine - Chicago
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What NCT05357040 shows while recruiting
NCT05357040 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05357040 reports a single indexed study location in Illinois, Victoria.
Frequently Asked Questions
What is clinical trial NCT05357040 about?
NCT05357040 is a clinical study titled "Antidepressant Effects of Nitrous Oxide". To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.
What is the current status of trial NCT05357040?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-06-30. Estimated completion is 2026-12-01.
What conditions does trial NCT05357040 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression.
What interventions are being tested in trial NCT05357040?
The interventions under investigation include: Placebo (DRUG), Nitrous oxide gas for inhalation (DRUG).
Who is sponsoring clinical trial NCT05357040?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357040 being conducted?
This trial has 2 study locations across Illinois, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357040's enrollment target sits among peer trials
172 90th of 282 higher than 193 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
- NCT05833334 · 172 participants · NA
Healthy Homes Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI